|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 中国消除麻疹的关键技术问题:专家解读共识显示文摘中国卫生部发布《2006—2012年全国消除麻疹行动计划》以来,全国采取了一系列消除麻疹策略与措施并取得明显进展,但中国处于消除麻疹的关键时期,面临着新的挑战,麻疹流行病学特征也发生了变化,尤其需要统一和澄清对一些技术问题的认识。中国疾病预防控制中心(Center for Disease Control and Prevention,CDC)免疫规划中心收集、汇总各级CDC专业人员近年来关注的问题,并会同世界卫生组织驻华代表处,组织国内外专家深人研讨了主要的技术问题,包括消除麻疹与接种疫苗、麻疹病例的传染来源、保护〈8月龄婴儿、爆发疫情的应急免疫活动、医院传播的作用和控制意义、特殊人群及场所等,形成专家解读共识,供相关部门和专业人员在消除麻疹中参考。 | 苏琪茹 徐爱强 Peter Strebel 许文波 郝利新 周勇 李慧 庞星火 马超 张燕 方刚 崔富强 丁峥嵘 沈永刚 安志杰 张永基 谢淑云 William Schluter 余文周 郑景山 夏伟 王青 郑慧贞 张延炀 张丽杰 段梦娟 杨维中 Lance Rodewald 李黎 罗会明 | 2014 | 中国疫苗和免疫2014，20，3： | 137 |
| 2 | 新型冠状病毒肺炎疫情紧急研究议程:传播和非药物缓疫策略显示文摘2019年12月29日,武汉市某医院报告了一起不明原因重症肺炎聚集性病例事件,中国政府核实后通报了世界卫生组织(WHO)[1]。2020年1月8日,此次暴发的病原被确认为新型冠状病毒,即2019新型冠状病毒(2019-nCoV),其基因序列被迅速提交WHO。1月30日,WHO宣布将新型冠状病毒感染的肺炎疫情列为'国际关注的突发公共卫生事件'[2]。病原确认后的1个月中,科学家们通过研究已经阐述了诸多重要问题,给疫情的理解、预测和防控带来很多帮助[1,3,4,5,6,7]。尽管我们对2019-nCoV的认识已逐步深入,但很多问题仍然缺乏答案或不够精确,亟待解决。 | 中国疾病预防控制中心新型冠状病毒肺炎疫情防控技术组 冯子健 陈秋兰 冯录召 李中杰 黎舒 秦颖 王晴 杨孝坤 殷文武 张慕丽 张婷 安志杰 李媛秋 吴丹 尹遵栋 俞海亮 陈伟 夏愔愔 张若尘 Lance Rodewald | 2020 | 中华流行病学杂志2020，41，2： | 35 |
| 3 | 新型冠状病毒疫苗研发进展和思考显示文摘2019年底中国武汉发生2019冠状病毒病(Coronavirus disease 2019,COVID-19)暴发疫情。2020年1月30日WHO宣布将该疫情列为国际关注的突发公共卫生事件,3月12日宣布为大流行。截至2020年4月3日,全球报告972303例COVID-19确诊病例,死亡50321例;其中中国报告82802例,死亡3331例。为应对COVID-19疫情进一步传播,多国已宣布启动COVID-19疫苗研发工作。本文综述了全球COVID-19疫苗研发的初步进展,并对疫苗研发和使用提出相关建议。 | 孙校金 王富珍 安志杰 Lance Rodewald 尹遵栋 | 2020 | 中国疫苗和免疫2020，26，3： | 13 |
| 4 | 中国推进消灭脊髓灰质炎终结战略计划技术问题:世界卫生组织专家解读显示文摘中国积极推进消灭脊髓灰质炎(脊灰)终结战略计划,分阶段将灭活脊灰病毒疫苗(Inactivated Poliovirus Vaccine,IPV)纳入免疫规划,预期2016年4月与全球同步停服三价(Trivalent)口服脊灰减毒活疫苗(Oral Poliomyelitis Attenuated Live Vaccine,t OPV),开始接种二价(Bivalent)OPV(b OPV)。为澄清对一些技术问题的认识,世界卫生组织驻中国代表处会同国内外相关专家,讨论了中国部分专业人员提出的主要技术和政策问题,包括停用OPV的原因,b OPV替代t OPV使用的步骤,转换前减少风险的准备等,形成专家解读,供相关部门和专业人员在推进消灭脊灰终结战略计划中参考。 | 左树岩 Lance Rodewald Roland Sutter Jackie Fournier-Caruana William Schluter Sergey Diorditsa | 2015 | 中国疫苗和免疫2015，21，4： | 9 |
| 5 | Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic,Pneumonia,and Severe Disease Caused by the Delta Variant:Real World Study and Evidence—China,2021显示文摘Summary What is already known about this topic?Effectiveness of China’s 2 inactivated vaccines(BBIBPCorV and CoronaVac)against pre-Delta severe acute respiratory syndrome coronavirus-2(SARS-CoV-2)variants ranged from 47%to over 90%,depending on the clinical endpoint,and with greater effectiveness against more severe coronavirus disease 2019(COVID-19).During an outbreak in Guangdong,inactivated vaccine effectiveness(VE)against the Delta variant was 70%for symptomatic infection and 100%for severe COVID-19.However,separate or combined VE estimates for the two inactivated vaccines against Delta are not available.What is added by this report?In an outbreak that started in a hospital,VEs of completed primary vaccination with inactivated COVID-19 vaccines against symptomatic COVID-19,COVID-19 pneumonia,and severe COVID-19 caused by the Delta variant were 51%,61%,and 82%.Completed primary vaccination reduced the risk of progressing from mild to moderate or severe COVID-19 by 74%.VE estimates for BBIBP-CorV and CoronaVac or combined vaccination were similar,and partial vaccination was ineffective.What are the implications for public health practice?Completed primary vaccination with either of the 2 inactivated COVID-19 vaccines reduces risk of symptomatic COVID-19,COVID-19 pneumonia,and severe COVID-19 caused by the Delta variant.Completion of the completed primary vaccination with two doses is necessary for protection from Delta. | Dan Wu Yanyang Zhang Lin Tang Fuzhen Wang Ying Ye Chao Ma Hui Zheng Wenzhou Yu Lei Cao Yifan Song Abuduwaili Reyimu Xiaoxiao Zhang Haifeng Wang Yifei Nie Mingxia Lu Muge Qi Jun Li Ruolin Wang Kaichao Yang Changshuang Wang Lawrence Everett Rodewald Geroge Fu Gao Zhijie An Zundong Yin | 2022 | China CDC weekly2022，4，4： | 7 |
| 6 | Effectiveness of Catch-Up Vaccinations after COVID-19 Containment--China,2020显示文摘Introduction:In the early stages of the coronavirus disease 2019(COVID-19)epidemic in China,the highest level of public health emergency response(Level 1 Response)was launched in all province-level administrative divisions(PLADs)across the country.Provision of vaccination services was selectively suspended due to the physical distancing and gathering restrictions required of Level 1 Response.The purpose of this paper is to evaluate the impact of COVID-19 on vaccination services and the effectiveness of selective vaccination service suspension and catch-up vaccinations in China.Methods:Vaccine doses administered,routine vaccination coverage levels,catch-up vaccine doses administered,and coverage levels after the catch-up campaign were determined from individual vaccination records in sampled clinics,standard routine immunization administrative coverage reports,and catch-up vaccination activity reports submitted by PLADs between October 2019 and October 2020.Results:National Immunization Program(NIP)and non-NIP vaccine doses administered in sampled clinics decreased by 80% and 90%,respectively,compared with doses administered before the COVID-19 pandemic.Coverage with the birth dose of hepatitis B vaccine(HepB1)and the Bacillus Calmette-Guérin vaccine(BCG)—two vaccinations recommended to continue throughout the epidemic due to their timecritical nature—were maintained at over 85%,while coverage of other NIP vaccines decreased to below 60%by February 2020.Catch-up vaccination coverage of the 29 PLADs,excluding Xinjiang and Xizang(Tibet),began in April 2020 and exceeded 90%;Hubei catch-up coverage was 95% by October 2020.Conclusions and Implications for Public Health Practice:The COVID-19 pandemic had a great impact on China’s vaccination services.During the epidemic and time of local transmission of the coronavirus,HepB1,BCG,rabies vaccine for postexposure prophylaxis,and tetanus antitoxin(TAT)for wound prophylaxis were maintained at high levels.Of the 69 million vaccine doses postponed during the time of local transmission of the coronavirus,94% were administered in the catch-up campaign.China’s pandemic immunization practices may provide evidence for other countries’immunization programs. | Jing Wu Wenzhou Yu Lei Cao Lingsheng Cao Lance Rodewald Jiakai Ye Yifan Song Li Li Xiaoxue Liu Ning Wen Fuzhen Wang Lixin Hao Yixing Li Hui Zheng Keli Li Chao Ma Dan Wu Yanmin Liu Guomin Zhang Zhijie An Huaqing Wang Zundong Yin | 2020 | China CDC weekly2020，2，50： | 6 |
| 7 | Compliance among infants exposed to hepatitis B virus in a post-vaccination serological testing program in four provinces in China显示文摘Background:Mother to child transmission of hepatitis B virus(HBV)remains the most common form of HBV infection in China.Prevention of HBV vertical transmission involves timely administration of the complete hepatitis B vaccine(HepB)series and hepatitis B immunoglobulin.Post-vaccination serological testing(PVST)is utilized to determine an infant's outcome after HBV exposure and completion of HepB series.We aim to determine the frequency of compliance with a PVST testing cascade for HBV infected mothers and analyze factors associated with infant lost to follow up(LTFU).Methods:We conducted a retrospeaive cohort review of previously collected data in Fujian,Jiangxi,Zhejiang and Chongqing provinces in China from 1 June 2016-31 December 2017.The study population included all HBV-exposed infants and their mothers.SAS software was used for statistical analyses.Bivariate and multivariate regression analyses(presented in odds ratio[OR]with 95%confidence intervals[CI])were used to compare the proportional differences of factors associated with PVST not being completed.Results:Among enrolled 8474 target infants,40%of them transferred out of the study provinces without further information and 4988 were eligible for PVST.We found 20%(994)of infants were not compliant with the testing cascade:55%of LTFU occurred because parents refused venous blood sample collection or failure of sample collection in the field,16%transferred out after 6 months of age,and 10%of families chose to have independent,confidential PVST completed without reporting results.High PVST noncompliance rates were more likely to be from Fujian(aOR=17.0,95%CI:9.7-29.9),Zhejiang(aOR=5.7,95%Cl:3.2-10.1)and Jiangxi(aOR=1.9,95%CI:1.0-3.4),and from HBV e antigen positive mother(aOR=1.2,95%CI:1.1-1.4).Conclusions:This study found that the LTFU rate reached 20%in PVST program,which was a significant problem.We recommend implementing a national elearonic information system for tracking HBV at risk mother-infant pairs;encourage further research in developing a less invasive means of completing PVST,and take effective measures nationally to reduce HBV stigma.Without reducing the loss to follow up rate among infants eligible for PVST,elimination of vertical HBV transmission will be impossible. | Hui Zheng Guo-Min Zhang Po-Lin Chan Fu-Zhen Wang Lance Everett Rodewald Ning Miao Xiao-Jin Sun Zun-Dong Yin Jeffrey Edwards Hua-Qing Wang | 2019 | Infectious Diseases of Poverty2019，8，4： | 5 |
| 8 | The National Immunization Advisory Committee in China:Roles of National Experts in Making Evidence-Based Recommendations for Immunization显示文摘In 2017,the State Council requested the National Health and Family Planning Commission(NHFPC),known as the Ministry of Health(MoH)before 2013 and as the National Health Commission(NHC)after 2018,to establish China’s National Immunization Advisory Committee(NIAC)(1).The NIAC acts as China’s National Immunization Technical Advisory Group(NITAG)—a deliberative body of national experts who advise national authorities and policy makers with evidence-based recommendations on immunization policy and program(2-3). | Chao Ma Lance Rodewald Zhijie An Zundong Yin Zijian Feng | 2019 | China CDC weekly2019，1，2： | 5 |
| 9 | Guangdong’s Study of the Effectiveness of China’s Inactivated Vaccines Against the SARS-CoV-2 B.1.617.2(Delta)Variant显示文摘Guangdong CDC published in preprint a critically important study of the effectiveness of China’s inactivated vaccines against the B.1.617.2(Delta)variant of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)—a strain of the virus that causes coronavirus disease 2019(COVID-19)and is circulating globally(1–2).The Delta variant managed to get through China’s strong international border quarantine protection and spark an outbreak in Guangdong Province in May–June 2021.While the outbreak was being stopped using guidance of the Protocol for Prevention and Control of COVID-19(3),the investigators took advantage of provisions in the Protocol that identified close contacts of anyone infected with SARS-CoV-2。 | Fuzhen Wang Zhijie An Lance Rodewald Dan Wu Lin Tang Hui Zheng Qianqian Liu George F.Gao Zundong Yin | 2021 | China CDC weekly2021，3，34： | 3 |
| 10 | Progress Toward Measles Elimination--China,January 2013-June 2019显示文摘What is already known about this topic?China has historically had high measles incidence and many associated deaths.A comprehensive measles elimination plan during 2006-2012 substantially reduced measles incidence;however,a resurgence occurred during 2013-2015.What is added by this report?In China,measles surveillance,outbreak response,research,and program evaluation were used to strengthen routine immunization and target immunization activities for eliminating measles.Measles incidence declined from 31 per million in 2015 to 2.8 in 2018;only one measles-associated death has been reported during 2018-June 2019.What are the implications for public health practice?The World Health Organization-recommended strategy to eliminate measles can be effective,including in large,densely populated countries like China. | Chao Ma Lance Rodewald Lixin Hao Qiru Su Yan Zhang Ning Wen Chunxiang Fan Hong Yang Huiming Luo Huaqing Wang James LGoodson Zundong Yin Zijian Feng | 2019 | China CDC weekly2019，1，2： | 3 |
| 11 | S olanum resistance genes against P hytophthora infestans and their corresponding avirulence genes显示文摘 | Jan Rodewald Bodo Trognitz | 2013 | Molecular Plant Pathology2013，，7： | 2 |
| 12 | Vaccinate with Confidence and Finish Strong显示文摘China’s sustained containment of the coronavirus disease 2019(COVID-19)epidemic has spared over 99%of the mainland of China’s 1.4 billion people from exposure to and infection with severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)and its variants for an astonishing two and a half years.Although the whole-of-government,whole-of-society containment effort has its own socioeconomic costs,the now-called dynamic COVID-zero strategy purchased a rare commodity—tranquil time with relatively little suffering and death from COVID-19 to develop and deploy tools for escaping the pandemic:diagnostics,vaccines,antivirals,and knowledge(1). | Lance Rodewald Dan Wu Zundong Yin Zijian Feng | 2022 | China CDC weekly2022，4，37： | 2 |
| 13 | Dependence of the coercivity Hci of high energy Nd-Fe-B magnets on the alignment coefficient显示文摘 | Rodewald W Wall B Blank R | 2000 | IEEE Trans on Magnetics2000，36，5： | 1 |
| 14 | Measurement of conductivity profiles in acceptor doped Strontium Titanatte显示文摘 | RODEWALD S FLEIG J MAIER J | 1999 | J Eur Ceram SOc1999，19，： | 1 |
| 15 | High - en- ergy sintered Nd - Dy - Fe - B magnets with Co and Cu additions 显示文摘 | Velicescu M Fernengel W Rodewald W | 1996 | J Magn Magn Mater1996，157，： | 1 |
| 16 | Intestinal absorption of immune complexes by neonatal rats:a route of antigen transfer from mother to young显示文摘 | Abrahamson D R Powers A Rodewald R | | 0，，4418： | 1 |
| 17 | 查看详情显示文摘 | Vergopoulos V Jantzen S Rodewald D | | 0，，： | 1 |
| 18 | Complete versus selective dry cow therapy for mastitis control显示文摘 | Rindsig R B Rodewald R G Smith A R | 1978 | J Dairy Res1978，61，： | 1 |
| 19 | 显示文摘 | Adler E Repple G W Rodewald W | 1990 | Int J Powder Metall1990，26，： | 1 |
| 20 | 显示文摘 | Velicescu M Fernengel W Rodewald W | 1996 | J Magn Magn Mater1996，471，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员